Dr Reddy's Laboratories Price to Free Cash Flow Ratio 2010-2024 | RDY

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

Dr Reddy's Laboratories average price to free cash flow ratio for 2024 was 66.66, a 274.07% increase from 2023.
Dr Reddy's Laboratories average price to free cash flow ratio for 2023 was 17.82, a 41.09% increase from 2022.
Dr Reddy's Laboratories average price to free cash flow ratio for 2022 was 30.25, a 60.97% decline from 2021.

Price to free cash flow ratio can be defined as

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

Dr Reddy's Laboratories average price to free cash flow ratio for 2024 was 66.66, a 274.07% increase from 2023.
Dr Reddy's Laboratories average price to free cash flow ratio for 2023 was 17.82, a 41.09% increase from 2022.
Dr Reddy's Laboratories average price to free cash flow ratio for 2022 was 30.25, a 60.97% decline from 2021.

Price to free cash flow ratio can be defined as

Related Stocks
Company Name	Market Cap
Teva Pharmaceutical Industries (TEVA)	$24.9B
BridgeBio Pharma (BBIO)	$6.8B
Bausch Health Cos (BHC)	$2.8B
Supernus Pharmaceuticals (SUPN)	$2.1B
Amphastar Pharmaceuticals (AMPH)	$1.7B
Personalis (PSNL)	$396M
Taysha Gene Therapies (TSHA)	$314M
Assembly Biosciences (ASMB)	$95M
Sol-Gel Technologies (SLGL)	$25M
Evoke Pharma (EVOK)	$6M
Teligent (TLGT)	$0M